Out of these 51 patients, 32 (64.7%) were men; 19 (37.2.5%) were either current or former smokers; 34 patients (66.7%) had an ECOG performance status of either 0 or 1; 47 (92.2%) had an adenocarcinoma; 43 (84.3%) had stage IV disease; 10 (19.6%) had a positive EGFR status; eight (15.7%) had a positive ALK status; and 38 patients (73.1%) had died by the cut-off date for this study. This evidence concerns the gene ALK and adenocarcinoma.